Table 2 Specific characteristics of included studies for hemoglobin decline (A), severe anemia (B) and ribavirin dose reduction or discontinuation (C)
Year | First author | ITPA Polymorphism | (A) Hemoglobin decline | (B) Severe anemia | (C) Ribavirin dose reduction or stop treatment | |||
|---|---|---|---|---|---|---|---|---|
Cut-off Hb | Time of analysis | Cut-off Hb | Time of analysis | Cut-off Hb | Time of analysis | |||
2010 | Fellay [8] | rs1127354 rs7270101 Haplotype | >3 g/dL | 4 weeks | <10 g/dL | 4 weeks | NR | NR |
2010 | Thompson [10] | Haplotype | >3 g/dL | 4 weeks | NR | NR | <8.5 g/dL | During treatment |
2010 | Sakamoto [15] | rs1127354 | >3 g/dL | 4 weeks | NR | NR | 8.5–10 g/dL | 4 weeks |
2011 | Thompson [16] | Haplotype | >3 g/dL | 4/12/24 weeks | NR | NR | <9.5 g/dL | During treatment |
2011 | Azakami [17] | rs1127354 | >2 g/dL | 4 weeks | NR | NR | <8.5 g/dL | During treatment |
2011 | Chayama [36] | rs1127354 | NR | NR | NR | NR | <12 g/dL | 12 weeks |
2011 | Kurosaki [18] | rs1127354 | >3 g/dL | 4 weeks During treatment | <10 g/dL | 4 weeks During treatment | NR | During treatment |
2011 | Rallón [19] | rs1127354 rs7270101 Haplotype | >2 g/dL | 4 weeks | NR | NR | NR | NR |
2012 | Nishimura [20] | rs1127354 | >3 g/dL | 4 weeks | <10 g/dL | 4 weeks | NR | NR |
2012 | Naggie [21] | Haplotype | >3 g/dL | 4 weeks | NR | NR | NR | NR |
2012 | Domingo [22] | rs1127354 | >3 g/dL | 4 weeks | NR | NR | NR | During treatment |
2012 | Osinusi [23] | Haplotype | >3 g/dL | 4 weeks | <10 g/dL | 4 weeks | NR | NR |
2012 | Miyamura [37] | rs1127354 | NR | NR | NR | NR | NR | 4 weeks |
2012 | Vidal [33] | rs1127354 | NR | NR | <10.5 g/dL | During treatment | NR | NR |
2012 | Tsubota [24] | rs1127354 | >3 g/dL | 4 weeks | <10 g/dL | 4 weeks | NR | NR |
2013 | Rau [25] | rs1127354 rs7270101 Haplotype | >3 g/dL | During treatment | NR | NR | NR | NR |
2013 | Di Marco [26] | Haplotype | >3 g/dL | 4 weeks | <10 g/dL | During treatment | NR | NR |
2013 | Ahmed [27] | rs1127354 | >3 g/dL | 4 weeks | <10 g/dL | 12 weeks | NR | 12 weeks |
2013 | Ogawa [34] | rs1127354 | NR | NR | <8.5 g/dL | During treatment | NR | 8–16 weeks |
2013 | Scherzer [28] | rs1127354 rs7270101 rs6051702 | >3 g/dL | 4 weeks | NR | NR | NR | NR |
2013 | Fujino [38] | rs1127354 | NR | NR | NR | NR | NR | During treatment |
2013 | D’Avolio [29] | rs1127354 rs7270101 rs6051702 | >3 g/dL | 4 weeks | NR | NR | NR | NR |
2013 | Clark [30] | Haplotype | >3 g/dL | 4 weeks | <10 g/dL | 4 weeks | 8.5–10 g/dL | During treatment |
2013 | Seto [39] | rs1127354 | NR | NR | NR | NR | 8.5–10 g/dL | During treatment |
2013 | Nakagawa [40] | rs1127354 | NR | NR | NR | NR | NR | 4 weeks |
2014 | Matsuura [31] | rs1127354 | >3 g/dL | 12 weeks | <10 g/dL | 12 weeks | NR | NR |
2014 | Rembeck [41] | Haplotype | NR | NR | NR | NR | NR | During treatment |
2014 | Aghemo [35] | Haplotype | NR | NR | <8.9 g/dL | During treatment | 8.5–10 g/dL | During treatment |
2014 | Hwang [32] | rs1127354 rs6051702 | >3 g/dL | 4 weeks | <10 g/dL NR | 4 weeks NR | NR | NR |